Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T18:02:36.634Z.
Calculation as of: 2026-10-06T18:02:36.634Z.
Quote observation: 2026-10-06T18:00:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84870b41b004d4a356f3546a7a12828ec10b1f950fc42869db9e2e4c5d55c05b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$533.14M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$509.97M
EV/FCF Ratio
936.20x
TTM Avg
716.21x
3Y Avg
716.21x
5Y Avg
716.21x
Market Cap
$531.17M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $520.57M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $516.33M | N/A | 0.12x | 0.12x | 0.12x |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $533.14M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $530.02M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $509.97M | 936.20x | 716.21x | 716.21x | 716.21x |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $531.17M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $507.94M | N/A | N/A | N/A | N/A |
| Allogene Therapeutics, Inc. (ALLO)vs › | $507.38M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $538.60M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $534.91M | 27.98x | 31.80x | 42.09x | 42.09x |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
